Catheter Precision Files 8-K: Material Agreements & Equity Sales

TL;DR

CPCI filed an 8-K detailing new material agreements and equity sales.

AI Summary

Catheter Precision, Inc. announced on October 25, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and material modifications to the rights of security holders. Additional details regarding financial statements and exhibits were also filed.

Why It Matters

This filing indicates significant corporate actions, including new agreements and equity transactions, which could impact the company's financial structure and shareholder rights.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• October 25, 2024 (date) — Date of earliest event reported
• Ra Medical Systems, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share VTAK NYSE American Indic
• $1.00 — s, priced at a public offering price of $1.00 per unit, with each unit consisting of
• $0.9999 — s, priced at a public offering price of $0.9999 per unit, with each unit consisting of
• $30.00 — hey each have a fixed exercise price of $30.00 per common share. Also as previously r
• $40.00 — ries E Warrant has an exercise price of $40.00 and a term of five years from date of t
• $0.70 — ries I Warrants from $1.00 per share to $0.70 per share, and also reduced the exercis
• $3.7 million — gregate gross proceeds of approximately $3.7 million from the exercise of the Existing Warra
• $1,185,000 — on received an additional approximately $1,185,000 upon the exercise of 1,010,000 Series H

Filing Documents

• rmed_8k.htm (8-K) — 37KB
• rmed_ex41.htm (EX-4.1) — 104KB
• rmed_ex101.htm (EX-10.1) — 79KB
• rmed_ex991.htm (EX-99.1) — 5KB
• 0001654954-24-013313.txt ( ) — 397KB
• rmed-20241025.xsd (EX-101.SCH) — 6KB
• rmed-20241025_lab.xml (EX-101.LAB) — 14KB
• rmed-20241025_cal.xml (EX-101.CAL) — 1KB
• rmed-20241025_pre.xml (EX-101.PRE) — 9KB
• rmed-20241025_def.xml (EX-101.DEF) — 2KB
• rmed_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Warrant Repricing As previously reported, on August 30, 2024, Catheter Precision, Inc., a Delaware corporation (the "Company"), entered into an Underwriting Agreement (the "Underwriting Agreement") with Ladenburg Thalmann & Co. Inc., as representative of the underwriters named in the Underwriting Agreement (the "Underwriters"), pursuant to which the Company issued and sold, in a firm commitment underwritten public offering by the Company (the "Public Offering"), (i) 805,900 common stock units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the five year anniversary of the date of issuance (a "Series J Warrant"), and (ii) 2,773,000 pre-funded units, priced at a public offering price of $0.9999 per unit, with each unit consisting of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001 per share that has no expiration date (a "Pre-Funded Warrant" and together with the Series H Warrants, Series I Warrants and Series J Warrants, the "Warrants"), one Series H Warrant, one Series I Warrant and one Series J Warrant. The Public Offering closed on September 3, 2024. Also, as previously reported, on January 9, 2023, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Armistice Master Fund Ltd. ("Armistice"). Pursuant to the Securities Purchase Agreement, Armistice agreed to purchase (a) Class A Units, each

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information disclosed in Item 1.01 of this Current Report on Form 8-K regarding the unregistered sale of the New Warrants, along with the New Warrant Shares issuable upon the exercise thereof, and the exercise of the modified Series F Warrants and the issuance of the shares of common stock in connection therewith, is incorporated herein by reference. The New Warrants described in Item 1.01 above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the New Warrant Shares issuable upon the exercise thereof, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

03. Material Modifications to Rights of Security Holders

Item 3.03. Material Modifications to Rights of Security Holders. The information disclosed in Item 1.01 of this Current Report on Form 8-K regarding the Inducement Letters is incorporated herein by reference.

01 Other Events

Item 8.01 Other Events. On October 25, 2024, the Company issued a press release announcing the Warrant Repricing. A copy of the press release is filed as Exhibit 99.1 and incorporated herein by reference. 3

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Description 4.1 Form of Series K Warrant. 10.1 Form of Warrant Inducement Offer Letter. 99.1 Press Release dated October 25, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL). 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: October 25, 2024 By: /s/ Margrit Thomassen Margrit Thomassen Interim Chief Financial Officer 5

View Full Filing

View this 8-K filing on SEC EDGAR